# UCLA UCLA Previously Published Works

# Title

Large-scale imputation of epigenomic datasets for systematic annotation of diverse human tissues

Permalink https://escholarship.org/uc/item/3b6029kz

**Journal** Nature Biotechnology, 33(4)

**ISSN** 1087-0156

# **Authors**

Ernst, Jason Kellis, Manolis

**Publication Date** 

2015-04-01

# DOI

10.1038/nbt.3157

# **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike License, available at <u>https://creativecommons.org/licenses/by-nc-sa/4.0/</u>

Peer reviewed



# **HHS Public Access**

Author manuscript *Nat Biotechnol*. Author manuscript; available in PMC 2015 October 01.

Published in final edited form as:

Nat Biotechnol. 2015 April; 33(4): 364-376. doi:10.1038/nbt.3157.

# Large-scale epigenome imputation improves data quality and disease variant enrichment

# Jason Ernst<sup>1,2,3,4,5</sup> and Manolis Kellis<sup>6,7</sup>

<sup>1</sup>Department of Biological Chemistry, University of California, Los Angeles, California, USA

<sup>2</sup>Computer Science Department, University of California, Los Angeles, California, USA

<sup>3</sup>Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Los Angeles, California, USA

<sup>4</sup>Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA

<sup>5</sup>Molecular Biology Institute, University of California, Los Angeles, California, USA

<sup>6</sup>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, Massachusetts, USA

<sup>7</sup>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

# Abstract

With hundreds of epigenomic maps, the opportunity arises to exploit the correlated nature of epigenetic signals, across both marks and samples, for large-scale prediction of additional datasets. Here, we undertake epigenome imputation by leveraging such correlations through an ensemble of regression trees. We impute 4,315 high-resolution signal maps, of which 26% are also experimentally observed. Imputed signal tracks show overall similarity to observed signals, and surpass experimental datasets in consistency, recovery of gene annotations, and enrichment for disease-associated variants. We use the imputed data to detect low quality experimental datasets, to find genomic sites with unexpected epigenomic signals, to define high-priority marks for new experiments, and to delineate chromatin states in 127 reference epigenomes spanning diverse tissues and cell types. Our imputed datasets provide the most comprehensive human regulatory annotation to date, and our approach and the ChromImpute software constitute a useful complement to large-scale experimental mapping of epigenomic information.

Competing Financial Interests

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial\_policies/license.html#terms

Correspondences should be addressed to J.E. (jason.ernst@ucla.edu) or M.K. (manoli@mit.edu).

Author Contributions

J.E. and M.K. developed the method, analyzed the results, and wrote the paper.

The authors declare no competing financial interests.

Availability of Imputed Signal Data, Imputation based Peak Calls and Chromatin States, and ChromImpute software All imputed signal datasets and peak calls and chromatin states based on imputed data are available from http://compbio.mit.edu/ roadmap. The ChromImpute software is available at http://www.biolchem.ucla.edu/labs/ernst/ChromImpute and source code is maintained at https://github.com/ernstlab/ChromImpute.

# Introduction

Genome-wide maps of epigenetic information, including histone modifications, DNA methylation, and open chromatin, have emerged as a powerful means to discover sample specific putative functional elements and to gain insights into the genetic and epigenetic basis of disease<sup>1-9</sup>. Given the dynamic nature of epigenomic datasets across samples and conditions, discovery power increases with broader coverage of diverse samples. However due to cost, time or sample material availability, it is not realistic to map every mark in every tissue, cell type and condition of interest. Additionally, some analyses are restricted to comparisons of only those marks that have been commonly mapped across different samples, leading to exclusion of marks or samples that did not have full coverage. An additional, often underappreciated issue is that even when a mark is mapped in a sample, it is usually done with few (if any) replicates, which can cause experimental variability, which confounds biological comparisons. This situation is exacerbated when analyzing large compendiums of datasets where the sheer number of datasets increases the likelihood that there will be outlier datasets of lower quality. Lastly, even for high quality experiments, robustness of the resulting signal level inferences may be reduced due to insufficient sequencing depth, especially for broadly-distributed marks that span a large fraction of the genome.

To address these challenges we developed ChromImpute, which uses a compendium of epigenomic maps, such as those generated by the NIH Roadmap Epigenomics and ENCODE projects<sup>2,10</sup>, to generate genome-wide predictions of epigenomic signal tracks, including histone marks, DNA accessibility, and DNA methylation (our method is generally applicable to any coordinate-based signal-track dataset, as we demonstrate with RNA-seq data). We predicted signal tracks of histone modifications, DNA accessibility (DNase hypersensitivity), and RNA-Seq at 25-base pair (bp) resolution and whole genome bi-sulfite (WGBS) DNA methylation data at single-nucleotide resolution (we refer to all of these data types as 'marks' for simplicity). We annotated a total of 127 reference epigenomes, including 111 generated by the Roadmap Epigenomics project<sup>10</sup> and 16 generated by the ENCODE project<sup>2,3</sup>. These span diverse cell types and tissues (we refer to them as 'samples' for simplicity, even though some reference epigenomes were based on multiple independent samples<sup>10</sup>).

We provide a systematic evaluation of the imputed data and demonstrate that the imputed data for a mark in a sample better matches the corresponding observed data than the observed data from any other sample. We also demonstrate how comparison between observed data and imputed data provides a state of the art data quality control metric that complements and surpasses existing methods. Even when a mark has been experimentally profiled in a sample, we show that imputed data is generally more consistent, robust, and accurate, as it leverages information from hundreds of datasets and thus is resilient to noise arising in individual experiments. The prior expectation of genome-wide signal provided by the imputed data can also be used in conjunction with observed datasets for inference of surprising signal locations in high-quality samples. We also use imputation quality using subsets of marks to provide recommendations and insights into experiment prioritization. Lastly, we use a compendium of 12 imputed marks in all 127 reference epigenomes to

predict and annotate a set of 25 chromatin states, providing the most comprehensive annotation of epigenomic state information in the human genome to date.

# Results

# ChromImpute method and previous work on imputation

Imputation has been previously explored in a number of bioinformatics settings. For microarray experiments, missing gene expression values have been predicted for specific genes in specific experiments<sup>11</sup>. For genome-wide association studies (GWAS), missing genotype values are routinely predicted for SNPs not directly assayed, by exploiting common haplotype structure<sup>12</sup>. For epigenomic datasets, prediction of both DNA methylation and histone modification datasets has been undertaken from DNA sequence information 13-15, but the static nature of genome sequence limits the ability to generate cell type-specific predictions for samples not previously used for training, as the motifs driving a given mark frequently differ across samples. Specifically for DNA methylation, imputation has been undertaken using sequence-based features and histone modification data from one sample<sup>16,17</sup>, for predicting high-resolution DNA methylation from lower-resolution assays in conjunction with sequence information and other annotations<sup>18</sup>, or by using an assumed phylogenetic relationships between cell types<sup>19</sup>. For histone modifications and other chromatin marks, methods have been developed by us and others, to infer chromatin states based on multiple marks, even in cases with missing data $^{20-22}$ , but these do not try to infer the actual signal for the missing marks. Several other methods have been developed to model correlations of histone marks with expression or with other marks in a single sample $^{23-26}$ , which have sometimes been leveraged for imputation on a limited scale, but have not considered across-sample information. In practice, studies interested in a given cell type sometimes use data from a related cell type, which can be viewed as one simple approach to imputation.

Here, we take an ensemble regression-based approach to epigenomic imputation. We impute each target mark in each target sample separately, by combining information from large numbers of datasets that were experimentally determined, but without using any data for the target mark in the target cell type (**Fig. 1a, S1**). We leverage two classes of features (see **Methods, Fig. 1d**):

- Same-sample (different-mark) information (**Fig. 1b**): The first class of features uses information from the signal of other marks mapped in the target sample, both at the target position and at neighboring sites.
- Same-mark (different-sample) information (**Fig. 1c**): The second class of features uses information from the signal of the specific mark of interest at the target position in the most similar samples. Similar samples are defined based on similarity with the signal of marks that have been mapped in the target sample both locally and globally (see **Methods**). The features in this class are effectively predictions that could be made by a K-nearest neighbor method for various values of K and distance functions.

As no training data is available for the target mark in the target sample, we learn the relationships between the features and the target mark using other samples that contain the target mark. We use regression trees<sup>27</sup>, as they can handle nonlinearities (including the constraint that signal values are non-negative), they support combinatorial interactions among features, and they are relatively fast to train. The prediction for each target mark in each target sample is based on an ensemble predictor that averages the values resulting from regression trees trained on each sample in which the target mark is available, thus reducing the impact of biases from any one individual predictor.

# Imputation of 4315 datasets in 127 reference epigenomes

We applied ChromImpute to a compendium of 127 reference epigenomes, including 111 profiled by the NIH Roadmap Epigenomics project<sup>10</sup> and 16 profiled by the ENCODE project<sup>2,3</sup> (**Fig. 1a**). These span diverse tissues and cell types, including Embryonic Stem Cells (ESCs), induced Pluripotent Stem Cells (iPSC), ESC-derived cells, blood and immune cells, skin, brain, adipose, muscle, heart, smooth muscle, digestive, liver, lung and others.

Only 5 'core' histone modification marks were experimentally profiled in all 127 reference epigenomes. These are promoter-associated H3K4me3, enhancer-associated H3K4me1, Polycomb repression-associated H3K27me3, transcription-associated H3K36me3 and heterochromatin-associated H3K9me3. Varying subsets of 34 marks were profiled in different epigenomes, including 30 histone modifications (11 histone methylation marks, 18 histone acetylation marks, and H3T11ph), histone variant H2A.Z, DNA accessibility, DNA methylation data, and RNA-seq data.

Based on these experimentally-profiled ('observed') datasets, we imputed the 31 marks observed in at least two epigenomes in all 127 epigenomes, and the three marks mapped in only one epigenome in the remaining 126 epigenomes. In total we generated 4,315 datasets based on imputation, of which only 1,122 (26%) were also experimentally mapped and 3,193 (74%) are only available as imputed data. Signal tracks for all marks were imputed at 25 base pair resolution (121 million predictions per track) except for DNA methylation, which was imputed at single-nucleotide resolution for each of 28 million CpGs. Across all marks, samples, and positions, we generated a total of 526 billion predicted signal values.

We categorized the 34 epigenomic marks into four classes according to the number of samples in which they were experimentally profiled and our imputation strategy (**Fig. S2**):

- Tier-1 marks were mapped broadly across samples, were used to impute all other datasets, and were imputed using only Tier-1 marks. They consist of H3K4me1, H3K4me3, H3K36me3, H3K27ac H3K27ac, H3K9ac, and DNA accessibility.
- Tier-2 marks were mapped broadly only in ENCODE samples, were used to impute Tier-2 and Tier-3 marks, and were imputed using only Tier-1 and Tier-2 marks. They consist of H3K4me2, H3K79me2, H4K20me1, and H2A.Z.
- Tier-3 marks had limited coverage, were only used to impute Tier-3 marks, and were imputed using all three Tiers. They consist of the remaining 20 histone modification marks.

 DNA methylation and RNA-seq datasets were treated separately. RNA-seq datasets were imputed using only Tier-1 marks and other RNA-seq datasets, and similarly DNA methylation datasets only using Tier-1 marks other DNA methylation datasets.

This tiered approach for histone marks and DNA accessibility datasets enables us to limit potential biases resulting from the lower number of samples for Tier-2 and Tier-3 marks (reducing only minimally the information available for making predictions), and to avoid confounders due to the very distinct nature of RNA-seq and DNA methylation datasets.

## Imputed datasets capture missing marks effectively

As an initial control, we assessed by visual inspection the level of similarity between pairs of matching imputed and observed datasets, using nine randomly-selected 200-kb regions and two thousand randomly-selected 25-bp regions. For the nine broad regions, we randomly selected one sample in which the mark was also experimentally profiled, and visualized imputed and observed tracks in detail (**Fig. 2a, S3**). For the two thousand samples, we generated a dense heatmap showing the observed and imputed mark signal across every sample in which both are available (**Fig. 2b, S4**). Both visual comparisons showed strong agreement between observed and imputed signal, successfully recovering epigenomic features at high resolution, across broad regions (**Fig. 2a, S3c**), and in a tissue-specific way (**Fig. 2b**). Beyond the visualizations provided in this paper, imputed and observed tracks are provided for the entire genome through public track hubs on the WashU epigenome browser (http://epigenomegateway.wustl.edu/browser/)<sup>28</sup> and the UCSC Genome Browser<sup>29</sup>.

We also assessed the ability of ChromImpute to predict missing marks using seven quantitative metrics: the genome-wide correlation between observed and imputed data ("GWcorr", Fig. 2c); the overlap between imputed and observed datasets in the top 1% of the 25-bp bins with the highest signal ("Match1"); the percentage of top 1% observed in top 5% imputed 25-bp bins ("Catch1obs"); the percentage of top 1% imputed in top 5% observed 25-bp bins ("Catch1imp") (Fig. S5-7); the recovery of top 1% observed and 1% imputed 25-bp bins based on the full range of signal of the other using the area under the curve (AUC) of a receiver operating characteristic curve ("AucObs1" and "AucImp1", Fig. S5-7); and the AUC recovery of bases covered by observed peak calls based on the full range of signal of the imputed data ("CatchPeakObs", Fig. S5-7). These 1% and 5% percentages are representative of the diversity of chromatin states for each mark (Fig. S8), and captured the majority of high-signal locations (Fig. 2b, S4; see also below, Fig. S14). For DNA methylation, we used GWcorr and "Methyl25", a previously-suggested concordance measure that considered two DNA methylation values in agreement if they were within 0.25 of each other<sup>30</sup>, as focusing on the top few percent of signal is less meaningful (since the vast majority of the human genome is highly methylated).

To provide perspective on the performance of ChromImpute in each metric, we compared it to two stringent baselines, which can be thought of as alternative imputation approaches. The first baseline, 'BestSingle', predicts a missing mark based on the signal of the most similar experimental dataset for the target mark, according to the specific metric measured

across any other sample. This metric is unrealistic, of course, as the most similar experiment is not known in advance, and is not available to ChromImpute, or to any prediction method. The second metric, 'SignalAvg', predicts the average signal of the target mark across all other samples.

ChromImpute showed strong recovery of observed datasets, both in its overall performance, and relative to both stringent baselines. For the GWcorr metric, ChromImpute showed 0.68 correlation on average per mark (vs. 0.49 for BestSingle and 0.50 for SignalAvg, **Fig. 2c**), outperforming BestSingle for 99% of datasets and SignalAvg for 91% of datasets per mark on average. ChromImpute showed AUC=0.95 recovery for Catch1 (vs. 0.84 and 0.88, **Fig. S5**) on average per-mark, and AUC=0.96 for CatchPeakObs (vs. 0.83 and 0.88) (**Fig. 2d**). For the Methyl25 metric, ChromImpute outperformed SignalAvg 97% of time, and BestSingle 76% of the time.

We also compared ChromImpute to several additional imputation approaches. First, we implemented ChromImpute-LR, using the same ensemble training strategy but linear regression instead of regression trees to combine features (**see Methods**). ChromImpute has overall similar or better performance than ChromImpute-LR for the Tier 1 and 2 marks and much better performance for DNA-methylation, although ChromImpute-LR shows somewhat better performance for some Tier 3 marks, which had fewer training datasets available (**Fig. S9**). Second, for Tier 1 histone marks in ES cells and iPSCs, we compared ChromImpute to a predictor based on averaging of increasingly large number of these near-replicate datasets (**Fig. S10**). Predictive power than 10 near-replicates for some marks, and 3 near-replicates for all marks (**Fig. S10**). Third, ChromImpute also outperformed nearest neighbor predictors of a mark based on local and global distance, a predictor trained on only one sample instead of the full ensemble (**Fig. S9**), and a predictor based on averaging active marks in the same sample to predict other active marks and likewise for repressive marks (**Fig. S11**), in each case supporting our imputation strategy.

# Increased robustness and annotated feature recovery

While the previous analyses demonstrated that imputed datasets provide a reasonable approximation to observed datasets, and thus can be beneficial when observed data is not available, we next investigated whether imputed datasets also have distinct advantages that make them valuable even if observed datasets are available. Two potential reasons may lead to advantages for imputed datasets: (1) imputed datasets are based on combining information from many experiments, and thus have the potential to be more robust to experimental noise and other confounders than the observed data; (2) by combining relevant information from many related experiments, imputed data can achieve a higher 'effective' sequencing depth, and thus potentially a higher signal-to-noise ratio.

We used the property that promoter-associated H3K4me3 frequently localizes near transcription start sites (TSS) and that transcription-associated H3K36me3 frequently localizes in gene bodies. We defined two metrics that quantify the extent to which the strongest H3K4me3 signal (at 25bp resolution) localizes within 2kb of annotated TSS ("PromRecov", **Fig. 3a**) and the strongest H3K36me3 signal localizes in gene bodies

("GeneRecov" **Fig. 3b**), using AUC for the portion of the receiver operating characteristic (ROC) curve that has a 5% false positive rate or less (we primarily focused on this metric instead of the full AUC as we expect many annotated locations to not be marked by the observed or imputed data in any one sample, but saw similar results based on the full AUC (**Fig. S12a,b**)).

We found that imputed data showed better annotation agreement than observed data for every dataset, often by a large margin (**Fig. S13**). In fact, the worst-performing imputed H3K4me3 dataset performed better than 96% of observed H3K4me3 datasets, and the worst performing imputed H3K36me3 dataset performed better than 91% observed datasets in the evaluations (**Fig. 3a,b**). Recovery of gene bodies for a few of the H3K36me3 observed datasets was only marginally above random, while for imputed data recovery was consistently high. Since these results are only based on the rank ordering of signal values, any normalization strategy which preserves the rank ordering (e.g. quantile normalization<sup>31</sup>) would not change these results. We also observed better overall agreement with annotated features when considering peak calls instead of signal level (**Fig. S14, see Methods**).

Additionally, imputed data showed a more robust and consistent signal profile than observed data. Observed H3K4me3 signal proximal to all TSSs shows up to 95-fold variation between samples (**Fig. 3c**), and observed H3K36me3 shows up to 7-fold variation in gene bodies (**Fig. 3d**). Suggesting that experimental variability indeed underlies some of these differences, rather than biological differences, two fetal brain samples (E081 and E082) showed large heterogeneity in their aggregate profiles for H3K4me3 and H3K36me3. E081 showed very flat distributions (**Fig. 3c,d**), while E082 and the imputed data for E081 and E082 all showed much more recognizable distributions (**Fig. 3c,d**). Consistent with experimental confounders, these E081 datasets were among the worst in both the PromRecov and GeneRecov metrics (**Fig. 3a,b**).

Imputed marks also showed higher consistency than observed marks in their genome-wide signal distribution (**Fig. S15**). For example, the observed datasets for H3K36me3 for the two fetal brain samples (E081 and E082) had 11.6 fold difference between the amount of the genome that had signal values 3 or greater, while imputed data show only 1.4-fold difference.

We also used the 28 marks that were mapped in two different ESC lines (H1 and H9) to compare near-replicates for observed and for imputed datasets. We expected that for high-quality datasets, each mark mapped in H1 should show a higher correlation with the corresponding mark in H9 than with other marks in H9 (and conversely for H9 marks). Indeed, this property held more frequently for imputed data vs. observed data (**Fig. S16**), once more supporting the increased quality of imputed datasets.

# Imputed data captures dynamics and sample relationships

To study whether imputed data can capture dynamic epigenomic information across cell types, we evaluated our PromRecov and GeneRecov metrics for tissue-restricted annotations, by focusing specifically on a set of the genes that were expressed in the corresponding samples (see **Methods, Fig. S12c,d, S13c,d**). Imputed data continued to

strongly outperform observed data for the set of expressed genes, with all but one imputed dataset for H3K4me3 showing higher PromRecov, and all imputed datasets for H3K36me3 showing better GeneRecov.

We also compared the ability of imputed and observed data to recover expressed genes as a function of the number of samples in which they were expressed (**Fig. S17**). Recovery of both TSS-proximal regions and gene bodies increased greatly with the number of samples in which a given gene is expressed for imputed marks (as expected given the multiple informant samples for each mark) and for observed marks (suggesting that genes detected as more broadly expressed show greater agreement with histone modification marks even for observed data). Notably, imputed H3K4me3 showed higher PromRecov independent of how restricted the expression was to certain samples, even for TSS regions of genes expressed in a single sample. For H3K36me3, observed marks showed a modestly higher recovery of gene bodies for genes expressed in only six samples or fewer (3% of expressed genes in a sample, on average). However, for the remaining genes expressed in increasing numbers of samples, imputed datasets consistently outperformed observed datasets.

For all Tier 1-3 marks, we directly compared the correlation between observed gene expression levels and the signal data for both observed and imputed marks (**Fig. S18**). For nearly all positively-correlated marks, imputed signal showed a greater positive correlation with gene expression than observed signal, both in TSS-proximal regions (**Fig. S18a**), and in gene bodies (**Fig. S18b**). For negatively-correlated marks, observed data showed greater negative correlation with expression than imputed data, but this higher negative correlation was associated with lower-quality observed datasets (**Fig. S18c,d**), and the difference was reduced when focusing only on higher-quality observed data, both in TSS-proximal regions (**Fig. S18c**) and in gene bodies (**Fig. S18d**).

We also evaluated the ability of both imputed and observed datasets to capture the relationships between tissues and cell types based on genome-wide correlation analysis between pairs of datasets (**Fig. 3e,f, S19**). Specifically we compared the imputed and observed data for their ability to group samples in accordance to their tissue group (defined in ref. <sup>10</sup> and shown in **Fig. 1a** of this paper) based on the correlation of individual marks (**Fig. 1, 3e**). We found the imputed data showed a correlation matrix with a strongly pronounced block structure, corresponding to the biological groupings of cell types and tissues. This was substantially weaker in observed datasets (**Fig. 3e**), suggesting imputed data better captures sample relationships.

To quantify this difference, we evaluated the ability of each Tier-1 mark, DNA-methylation, and RNA-seq to distinguish same-group vs. different-group sample pairs (excluding the heterogeneous 'ENCODE' and 'Other' groups), based on the relative genome-wide pairwise correlation, evaluated as the AUC for both observed and imputed signal (**Fig. 3f**). Imputed data consistently out-performed observed data, showing an average AUC of 0.92 vs. 0.79 for observed data. The increase in classification power was most pronounced for H3K4me3, H3K36me3, H3K27me3, and H3K9me3, which are generally considered less cell type specific (AUC=0.93 vs. 0.70).

These results also held for sample group classification based on histone mark peak call similarity (**Fig. S20**), when trying to distinguish pairs of samples having the same anatomy annotation from those that have a different one<sup>10</sup> (with all marks except DNA methylation showing increased accuracy, **Fig. S20**, **Table S1**), and for higher-resolution distinctions beyond the tissue group level, as ChromImpute predictions showed higher correlation with corresponding observed data than predictions obtained by averaging all same-group experiments (**Fig. S21**). We reasoned that perhaps a weighted average of observed and imputed data may further improve classification power, but we did not see substantial improvement in a combination approach relative to just using the imputed data, except for DNA methylation where a balanced combination showed the highest classification (**Fig. S22**).

### Imputed data improves GWAS enrichments

As epigenomic maps have recently emerged as an unbiased approach for discovering disease-relevant tissues and cell types<sup>3,32</sup>, we also evaluated the impact of epigenome imputation on the interpretation of trait-associated variants from GWAS. We quantified the enrichment (positive or negative) of trait-associated variants from the NHGRI GWAS catalog<sup>33</sup> in both observed and imputed datasets for each mark. We evaluated enrichments both in aggregate across all studies, based on Area under an ROC curve up to a 5% false positive rate (AUC5%) for the signal level recovery of trait-associated SNPs, and at the level of individual studies, based on mark signal rank differences between each study's SNPs and all other SNPs in the GWAS catalog (**see Methods**). We evaluated both the number of studies for which there was a significant signal rank difference in at least one sample, and the total number of study-sample pairs that are significant, at varying p-value thresholds. We then compared both the number of significant studies and the number of significant pairs to the numbers obtained for randomized versions of the GWAS catalog, which also enabled us to obtain a false discovery rate estimate for each p-value threshold (**Table S2, see Methods**).

For all Tier-1 active marks, imputed data resulted in substantially greater recovery of SNPs in the GWAS catalog (**Fig. S23**) than the observed data, and more significant enrichments for both the number of studies, and the number of study-sample pairs, across all tested significance thresholds (**Fig. 4a, Fig. S24-S25**). In addition, the imputed data yielded a stronger enrichment for each enriched sample in the large majority of cases for nearly all marks (**Fig. 4b, Fig. S26**). We confirmed that the actual GWAS catalog yielded more significant associations than randomized versions, for both the observed and imputed data (**Fig. 4a, Fig. S24-S25**). Imputed data performance was substantially higher than that of the average mark signal across all available samples (**Fig. S24b**), emphasizing the increased performance was not simply due to averaging multiple samples. We also confirmed that the top most significant enriched samples for a given study were generally biologically relevant for active marks: for H3K27ac for example, we found that liver was enriched in various cholesterol phenotypes, that immune-related cells were enriched in various immune related disorders, ulcerative colitis in the colonic mucosa and many other biologically-meaningful enrichments (**Fig. 4c-f, Table S2**).

These results help validate the biological relevance of imputed datasets based on an orthogonal annotation source, and help illustrate imputed datasets as a potentially useful resource for interpreting GWAS results.

# Imputed datasets are informative for quality control

We next studied whether discrepancy between imputed and observed datasets is indicative of lower-quality experiments and can be used as a quality control (QC) metric. We ranked all H3K4me3 and H3K36me3 datasets based on PromRecov and GeneRecov scores respectively, providing an independent benchmark informative of dataset quality (**Fig. 5a**). We then compared several QC metrics previously applied to these datasets<sup>10</sup> based on their ability to flag the worst-ranked datasets. These metrics are based on the proportion of reads falling in enriched regions as determined by various methods (Signal Proportion of Tags (SPOT)<sup>34</sup>, pre-binned regions enriched based on a Poisson distribution<sup>10</sup>, and FindPeaks<sup>35</sup>), and signal correlations between forward and reverse reads (normalized strand correlation (NSC) and relative strand cross-correlation (RSC))<sup>36</sup>.

Traditional QC metrics indeed flagged several worst-ranked H3K4me3 and H3K36me3 datasets, but failed to detect several cases, especially for lower read depths. This was more pronounced for H3K36me3, where two metrics (NSC, RSC) failed to detect the majority of low-GeneRecov datasets, and several datasets (E104, E022, E087, E109) were not detected as problematic by any of the traditional QC metrics. A deeper understanding of the sources of lower-quality datasets is beyond the scope of this paper, but the low read depth of several flagged datasets (**Fig. 5a, S27**) suggests that deeper sequencing in some cases could improve overall quality.

By contrast, imputation-based QC metrics were consistently able to capture worst-ranked datasets, even when traditional QC metrics failed (**Fig. 5a**). We evaluated two imputation-based QC metrics, the first based on our Match1 score (overlap of the top 1% of imputed signal with observed signal) (**Fig. S8**) and the second based on our GWcorr score (genomewide correlation in signal between imputed and observed signal tracks). Both performed well, showing the best agreement with PromRecov and GeneRecov at detecting the worst datasets (**Fig. 5a**). Notably, the E104 Right Atrium H3K36me3 dataset (which both the GeneRecov and imputation metrics ranked as the worst H3K36me3 dataset) was rated as the single highest-quality H3K36me3 dataset based on the NSC metric, and was considered among the ten highest-quality H3K36me3 datasets by SPOT. The meta-gene plot of this sample shows inconsistencies with the typical pattern for H3K36me3 and is suggestive of potential antibody cross-reactivity (**Fig. 5d**), illustrating how QC measures based on agreement with imputed data can be used to identify likely problematic datasets that are missed by other metrics that are ineffective in cases of label swaps or antibody cross-reactivity.

Observed datasets varied substantially in their agreement with their corresponding imputed datasets (**Fig. 5b, S28, Table S3**). Moreover, the observed signal tracks for the worst-scoring samples (Match1 metric) showed striking visual differences from the best samples, whereas the corresponding imputed signal tracks had a consistently strong signal (**Fig. 5c,d**). When correlating QC metrics and read depth across all samples (**Fig. S27**), the GWcorr

metric showed among the highest correlations with both PromRecov and GeneRecov, and was better correlated with sequencing depth for all histone marks, while being distinct from other QC metrics for all marks, highlighting that imputation-based QC measures capture important information that is complementary from existing QC metrics.

## Imputed data prior identifies unexpected signal regions

While many high-quality experiments will globally agree with the imputed data, there could be specific locations for which the imputed data does not match the observed data. Since the imputed data constitutes a form of prior expectation on the observed data, genomic locations where the two disagree can pinpoint biologically-interesting locations and in some cases tissue-specific regulatory drivers.

To investigate this application of imputed datasets, we analyzed genomic locations showing strong DNA accessibility in observed data but weak or no DNA accessibility in imputed data (**see Methods**). Sequence motif analysis of these locations revealed an enrichment of biologically-relevant regulatory motifs with known cell-type specific roles (**Fig. S29**). For example NFKB motifs were found using Primary monocyte DNA accessibility (E029) consistent with immune regulation, and PAX2<sup>37</sup> motifs in Fetal Kidney DNA accessibility (E086) consistent with roles in kidney development.

Thus, even for high-quality datasets, building a prior expectation of signal across the entire genome can also be informative for identifying locally-dissimilar locations, which may be associated with cell type-specific and tissue-specific regulatory processes. However, if a mark that is highly-correlated with the mark of interest is already present, then the imputation will already provide a close enough approximation to the true signal that dissimilar locations may be due to biological or experimental noise, rather than cell type-specific regulation.

# Imputation feature usage varies across marks

We next sought to gain information about the utilization of different marks and features for imputing datasets. We first studied the frequency with which each feature was utilized in our regression trees, at the root (**Fig. S30a**) or at any position (**Fig. S30b, S31**) when it was available. We did this both for the primary imputation analyzed above, treating Tier-1, Tier-2, and Tier-3 marks separately given their differences in coverage, and only for the seven samples with deep coverage of many marks<sup>10,9</sup>, treating all Tier 1-3 marks uniformly given their similar coverage.

For nearly all acetylation marks, the most frequent feature at the root was another acetylation mark at the same genomic position in the same sample, reflecting the highly correlated and dynamic nature of acetylation marks. For H3K36me3, H3K27me3, H3K9me3, H3K4me3, DNA accessibility, RNA-seq, and DNA methylation, the most informative feature for the root was based on the same mark in the nearest K samples, consistent with their much more stable nature across cell types.

When considering any position in the regression tree, the most frequently used features were from other marks in the same sample and the same position, although all positions

surrounding the target genomic location were used substantially (**Fig. S31**). DNA accessibility was less frequently used at the exact target position compared to histone mark features (**Fig. S31**), reflecting the slight displacement of nucleosomes relative to openchromatin regions, and thus the offset of histone modification marks relative to DNA accessibility peaks.

#### Chromatin state annotation using many imputed marks

Given the importance of chromatin mark combinations for distinguishing biologicallymeaingful features and different classes of regulatory elements, we used ChromHMM<sup>20,21</sup> to discover chromatin states based on imputed marks. Chromatin state analysis in the Roadmap Epigenomics project was limited to only 5 marks in all 127 samples (H3K4me1, H3K4me3, H3K36me3, H3K27me3, and H3K9me3), or only 6 marks (with H3K27ac) for 98 samples<sup>10</sup>, with the number of samples rapidly decreasing as additional marks are considered due to missing datasets. ChromHMM explicitly handles missing data, but absence of a particular mark can result in dramatic reduction in the genomic coverage of corresponding chromatin states in the samples that are missing a defining mark (e.g. a DNA accessibility dominated chromatin state shows 60-fold reduction for samples that lack DNA accessibility, **Fig. S32**). Epigenomic mark imputation circumvents these limitations and provides a practical alternative to the missing-data strategy of ChromHMM, enabling learning of chromatin states jointly on uniform signal tracks for large numbers of epigenomic features across large numbers of samples.

We first learned a 25-state model jointly<sup>3</sup> across all 127 samples (Fig. 6b,c) using all Tier-1 and 2 marks. This captured multiple types of promoter, enhancer, open chromatin, transcribed, and repressed states and shows specific DNA methylation and RNA-seq enrichments (Fig. 6b,c, S33). Compared to the 15-state chromatin state model based on observed data in the 127 samples (Fig. S33), the 12-mark model better distinguished active vs. poised enhancer states (using H3K27ac and H3K9ac), and captured novel states (e.g. state 19 DNase showing DNA accessibility but lacking enhancer/promoters marks and state 5 T $\times$ 5' associated with 5'ends of transcripts and based on H3K79me2). Benefiting from the increased stability and robustness of imputed data, imputation-based chromatin states showed more consistent genome coverage across tissue/samples (Fig. S34), better agreement with annotated gene bodies and transcription start sites, both for all transcripts (Fig. S35a,b) and for the set of transcripts expressed in a given tissue (Fig. S35c,d), and better discrimination of evolutionarily-conserved elements (Fig. S36)<sup>38</sup>. Additionally we saw better recovery of samples that were not included in any of our training data (e.g. an osteoblast DNA accessibility dataset<sup>39</sup>, Fig. S37), while capturing major cell type specific differences in chromatin states (e.g. ESC/iPSC cell types showing consistently more abundant bivalent promoter states<sup>40</sup>, Fig. S38), with cell type specific differences even more pronounced than for chromatin states based on observed data (Fig. S38).

We also learned a 50-state model using imputed data for 29 marks across the seven deeplycovered samples. The model showed distinct state emission parameters, diverse functional enrichments, and relatively consistent correlations in emission parameters and mark frequency across samples for nearly all states (**Fig. 5d, S39-41**).

# Accurate imputation using limited numbers of marks

To help priorize marks for experimental profiling in new cell types, we studied the subset of marks that provide the highest-accuracy imputation. We considered two settings, the first ('unrelated setting') assuming that new samples are largely dissimilar to any existing in the compendium and can only rely on same-sample features, and the second ('related setting') for samples that are related to the existing compendium of datasets with roughly uniform coverage of each mark to impute a new cell type.

In both settings, we assessed the predictive power of a subset of features by comparing the agreement achieved between observed and imputed signal using the subset of features, relative to the agreement achieved using all features. We chose this 'relative agreement' metric to avoid penalizing the prediction of marks that are hard to impute even when using all features (possibly due to low-quality signal). We evaluated this relative agreement using the Match1 metric (except for DNA methylation, where we used Methyl25), and using the coefficient of determination ( $\mathbb{R}^2$ ). We restricted these evaluations to the seven deep-coverage samples on chr10 and did not make distinctions between the Tier 1-3 marks (**Fig. S8**)

In the 'unrelated' setting (same-sample features only), imputation of H3K36me3, H3K9me3, H3K27me3, and RNA-seq showed the lowest relative Match1 scores (20-39%) (**Fig. 6a, S42a**), followed by DNA accessibility (70%), H3K79me2 (82%), and H3K4me1/2/3, H2A.Z, and H3K79me1 (92-93%), suggesting a prioritization based on the marks that are hardest to impute using same-sample features, even if all other marks are used. All acetylation marks showed higher relative Match1 scores (97-100%), but H3K27ac had the lowest relative score among them (97%), suggesting it contains the most unique information. Relative Match1 score recovery was 87% on average across all marks when using all same-sample features, 70% when using only the five core marks (counting experimentally-mapped marks as 100% recovered), 73% using the core marks and either DNA accessibility or H3K9ac, 78% using the core marks and DNA accessibility, and 85% using all Tier 1-2 marks (**Fig. 6a, S42a**). R<sup>2</sup> recovery showed overall similar results and conclusions, but revealed a lower overall agreement for DNA methylation (**Fig. S42b**), also highlighting its unique information relative to other marks in the same sample.

In the 'related' setting (both same-sample and same-mark features), the five 'core' modifications resulted in 80% Match1 relative recovery on average across all marks, which increased respectively to 86%, 82%, and 81% with inclusion of H3K27ac, H3K9ac, or DNA accessibility, and increased to 89% using all tier 1 and 2 marks (**Fig. 6a**). Recovery of acetylation marks was on average lower (66%) using only the five core marks, but increased to 77%, 71%, and 68% respectively with inclusion of H3K27ac, H3K9ac, or DNA accessibility. Using one or two marks led to sometimes surprisingly high recovery of many other marks. For example, H3K18ac alone resulted in 87% average recovery across all others marks (88% for acetylation marks), and greater than 80% recovery for all marks except H4K20me1, H3K79me1 and H3K23me2. Profiling of H3K79me2 was highly complementary, resulting in 98% recovery for H4K20me1 and H3K79me1, and in combination with H3K18ac resulted in 90% average recovery of marks in a new cell type,

when leveraging the entire existing data compendium -- but only 71% average recovery using same-sample features.

We also used chromatin states to evaluate the 'unrelated' setting, based on the ability of subsets of the 29 marks to recover each of the 50 chromatin states learned from imputed data in the seven deeply-covered samples when treating the remaining marks as missing<sup>20</sup> (**Fig** 6d, S43; see Methods). We found that holding out any of DNA accessibility, H3K9me3, H3K36me3, H3K4me1, H3K27me3, or H3K27ac resulted in at least one 'missing' state (less than 20% recovery) (Fig S43). No single mark in isolation led to substantial state recovery beyond the states that were primarily defined by that mark (Fig. S43d). Holding out any of H2A.Z, H3K79me2, H4K20me1, H3K79me1, H3K4me3, or H3K4me2 resulted in at least one state with less than 70% recovery. Using only the five core marks and treating all remaining marks as missing data resulted in 31% average recovery of assigned locations for each state (Fig 6d, S43c). Including any of H3K27ac, H3K9ac or DNA accessibility increased average recovery to only 35-37%, and the greatest average state recovery of any mark was 43% with the additional inclusion of H3K18ac. Using all Tier 1 and 2 marks together increased the average recovery to 65%, with only 12 states showing 30% or less recovery (Fig. 6d, S43b). Inclusion of H3K18ac with the Tier-1 and Tier-2 marks increased average state recovery to 77%, with all states showing greater than 30% recovery. These results suggest substantial additional diversity of chromatin states not captured based on the chromatin marks that have received extensive mapping by the Roadmap Epigenomics and ENCODE projects.

# Discussion

In this paper we introduced a computational approach for prediction (imputation) of genome-wide epigenomic signals applied at 25-nucleotide resolution. The method imputes both missing and existing datasets by leveraging correlations of epigenomic marks within a given sample, and similarities in the epigenomic landscape of related samples, and it is applicable to any type of functional data that can be represented as a signal track. We developed and applied an array of quantitative metrics and tests to evaluate the accuracy of the imputed data. We showed that the imputed data signal is of high resolution, and a better match to observed data signal than using the average of all observed datasets of that type (an important baseline comparison for any such study), and it is also a better match than even the single closest dataset (a benchmark that would require knowledge of the target mark, and is thus not possible in practice).

We showed that imputed data outperforms observed data based on a number of analyses: (1) similarity to annotated gene features; (2) consistency across closely related samples; (3) capture of biological relationships between tissue/cell types; (4) correlation with observed gene expression; (5) enrichment of SNPs identified in GWAS; (6) chromatin state capture of transcription start sites, gene bodies, tissue-restricted activity, and conserved elements. The observed data were only advantageous in identifying genes with the most tissue-specific expression patterns (only 3% of genes). Furthermore, disagreement between observed and imputed data was usually due to lower quality experimental datasets, and not low-quality imputation.

Our benchmarks show that in practice, observed data is not always an uncontested goldstandard, but that both observed and imputed data are of important and complementary value, each with its own merits, and each likely to have both false negative and positive signals. Certainly, when high-quality, deeply-sequenced, and extensively-replicated experiments are available, they remain a gold standard. However, with the reality of budgetary and sample limitations, our work establishes imputed data as an important complement to experimental studies. For any fixed number of budgeted experiments, imputation allows projects to explore a larger diversity of samples, assays, or conditions, and to increase robustness by leveraging automatically-learned correlations in these datasets, rather than relying solely on direct experimental profiling and replicates to increase robustness. Moreover, replicates are not always available, do not determine which replicate is problematic in case of disagreement, and do not handle the situation when both replicates have the same confounding factors, while imputation-based QC addresses all these cases.

Moreover, the combined use of observed and imputed data opens many new applications that were previously not possible. Imputed data can be used as a prior expectation for an experiment, against which observed data can be compared and benchmarked. We demonstrated two applications of such comparisons, using global discrepancies between observed and imputed data as a QC metric, and identifying surprising locations which we found enriched for regulator targets. For QC in particular, we showed that low agreement between imputed and observed data revealed problematic datasets that were missed by many existing metrics that focus on signal-to-noise properties of the data, and thus can miss sample mix-ups, cross-reacting antibodies, or other experimental errors. With more densely sampled epigenomic datasets, we expect that next-generation QC metrics will increasingly exploit imputation-like measures, such as our stringent baselines defined earlier, or the more sophisticated agreement with ChromImpute.

Our work also has implications for experiment prioritization for large scale epigenomic mapping efforts. The Roadmap Epigenomics project mapped a set of six histone marks at highest depth: H3K4me1, H3K4me3, H3K27me3, H3K9me3, H3K36me3, and H3K27ac. Our results validate this strategy, as H3K27me3, H3K9me3, and H3K36me3 could not be imputed effectively using same sample data even if every other mark in the same sample was mapped, and H3K4me1, H3K4me3, and H3K27ac all had substantial unique information that could not be predicted from just using same sample features of the other five marks. Our results propose extending this core set with H3K18ac, which led to better imputation of non-H3K27ac acetylations, and H3K79me2, which led to better capture of transcription-associated marks. Both marks have evidence of being important in their own right, in pathogen response<sup>41</sup> and cancer<sup>42–45</sup> for H3K18ac, and in epigenetic memory<sup>46</sup>, development and cancer<sup>47</sup> for H3K79me2.

It is also important to recognize limitations of the imputation approach. If the presence of mark signal is highly specific to one or a few samples and it does not correlate with other marks mapped in the sample or has a different correlation structure than in samples used for training, then it would not be possible to accurately impute the mark at those locations. When the target mark has been mapped in only few samples, the features pertaining to the same mark in other samples may be less informative or more biased. For example,

imputation of transcription factor (TF) binding may be more challenging, as their correlation structure with other marks can vary greatly across samples, depending on whether a TF is active or not, and most have only been mapped in a limited number of samples. A limitation of our current framework when imputing datasets across individuals is that we do not currently incorporate genetic variation as an input, and this is potentially an important area of future development given increasingly-available datasets on chromatin marks and genotype across individuals<sup>48–50</sup>. For tissue samples that reflect mixtures of multiple cell types, our imputed maps will most likely reflect the same mixture as the observed data, though deconvolution of mixed samples is a potentially important direction for future work.

Lastly, our paper contributes the most comprehensive epigenomic resource to date, including 4,315 imputed datasets across 127 samples and 34 marks (of which only 26% have been experimentally profiled). The remaining 74% (3193 datasets) only exist as imputed data, dramatically expanding the number, diversity, and completeness of even the most complete existing epigenomic maps. We also provide an annotation of 25 chromatin states based on 12 imputed marks across 127 samples, and of 50 chromatin states based on 29 epigenomic marks across 7 samples, providing the most comprehensive collection of regulatory annotations across the human genome to date. As our initial analyses demonstrate, the resulting annotation of the non-coding portion of the human genome can increase the power of future studies of gene regulation, cellular differentiation, genetic variation, and human disease.

# **Online Methods**

#### Signal Tracks

For the histone mark and DNase signal tracks we used the version of the reference epigenomes signal tracks based on the  $-\log_{10}$  P-value of enrichment relative to input control based on a Poisson distribution from (Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup> available through http://compbio.mit.edu/roadmap/. Some of these reference epigenomes are based on multiple biological samples that were pooled, but we refer to each reference epigenome as a 'sample' here. We only used the signal for chromosomes 1-22 and X. For the RNA-Seq data we converted the uniformly processed unstranded signal tracks, also available from the same site, to normalized RPKM values, then added one, and then took the log base 2 value. The normalized RPKM values were computed based on multiplying the unnormalized signal value by  $10^9$  then dividing by the product of the read length and the number of exonic reads excluding the mitochondria, ribosome, and the top 0.5% of signal values<sup>10</sup>. We converted these signal tracks for the histone marks, DNase, and RNA-seq data to a 25bp resolution by taking the base level average of signal overlapping each 25bp-bin. For the DNA methylation we used the uniformly processed whole genome bi-sulfite data<sup>10</sup>, which provided a fraction methylated value at each base within all CpGs that had more than 3 reads covering it. We filled in missing values for bases within CpGs by replacing them with the genome average for DNA methylation when training and the chromosome average when applying the predictors as this step was done on each chromosome independently.

We selected the  $-\log_{10}$  p-value signal tracks opposed to the fold change tracks for histone marks and DNase as they were designated the primary signal tracks for analyses in

(Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup> based on having better signal to noise properties. In particular both sets of tracks were generated based on down-sampling highly sequenced datasets to the same sequencing depth, thus in the  $-\log_{10}$  p-value track no dataset had a disproportionately high signal simply due to being sequenced very deeply, while on the other hand under-sequenced datasets were included and in some cases had locations with high fold change signal that were the result of noise and did not have as high values on the  $-\log_{10}$  p-value track. Additionally focusing on the  $-\log_{10}$  p-value tracks is more consistent with the basis of default binarization of ChromHMM<sup>21</sup> used for the chromatin state learning.

## **ChromImpute Method**

The ChromImpute method predicts the signal of a target mark in a target sample based on two classes of features: (1) other marks mapped in the same sample and (2) the target mark in other samples. Predictors that integrate these features are trained based on each sample for which we have the target mark available excluding the target sample. The ensemble of trained predictors are then each applied in the target sample and their predictions are averaged to obtain the final predictions. The ensemble approach would be expected to tend to average out biases associated with any one predictor.

Formally, let  $o_{c,m,p}$  represent the observed value of mark m in sample c at position p. Let  $M_{c,m}$  denote the set of marks in sample c among those eligible to be used to predict mark m. Let  $C_m$  denote the set of samples in which mark m has been mapped. Let  $m^t$  denote the target mark and  $c^t$  the target sample. To predict mark  $m^t$  in sample  $c^t$  for each sample  $c^{t'} \in C_m^t \{c^t\}$  we separately define features. For a sample  $c^{t'}$  we let  $M_I$  denote

 $M_{c^t,m^t} \cap M_{c^{t'},m^t} \setminus \{m^t\}$  which is the subset of common marks between  $c^t$  and  $c^{t'}$  that can be used to predict the target mark  $m^t$ , and then define the two classes of features to predict the signal of mark  $m^t$  in sample  $c^{t'}$  at a target genomic position p:

- Features based on the set of other marks mapped in the same sample: We define features *s<sub>m,n</sub>* for each mark *m*∈*M<sub>I</sub>* and each value of *n* such that *n*=500*i* or *n*=25*i* for integer values of *i*=-20,...,20. The feature *s<sub>m,n</sub>* is assigned a value *o<sub>c</sub><sup>t'</sup>*,*m,p*+*n*. In our notation *p*+*n* refers to a position on the same chromosome as *p*, but a base position shifted by *n*. This corresponds to having features at the target position and every 25bp within 500bp, and every 500bp within 10,000bp both upstream and downstream of the target position.
- Features based on the target mark in other samples: We define features *f<sub>m,g,k</sub>* for each mark *m*∈*M<sub>I</sub>*, *g*∈{*local,global*}, and *k*=1,...,min(10,|C<sub>I</sub>|) where we define *C<sub>I</sub>* to be *C<sub>m</sub><sup>t</sup>*∩*C<sub>m</sub>*{c<sup>t'</sup>,c<sup>t</sup>}. *C<sub>I</sub>* corresponds to all samples having the target mark and the mark that will be used for determining similar samples excluding the overall target sample and the sample being used for training the predictor. *f<sub>m,g,k</sub>* has the value

 $\frac{1}{k} \sum_{j=1}^{k} o_{c_j,m,p}$  where  $c_j$  is the sample of  $C_I$  that is in the ranked position j when each sample  $c \in C_I$  is ordered in increasing value of  $d_{m,g}(c^{t'}, c)$ . If g=global, then  $d_{m,g}(c^{t'}, c)=1-\rho(o_c^{t'}, m, o_{c,m})$  where  $\rho$  is the pearson correlation coefficient applied to the genome-wide signal of mark m in samples  $c^{t'}$  and c. If g=local, then at the

position  $p d_{m,g}(c^{t'}c) = \sum_{i=-20}^{20} \left( o_{c^{t'},m,p+25i} - o_{c,m,p+25i} \right)^2$  which uses the signal at target position and every 25bp interval within 500bp to determine the nearest samples. Ties for the nearest sample based on local distance were broken arbitrarily.

We construct feature vectors by combining all the  $s_{m,n}$  and  $f_{m,g,k}$  features defined above. Features when applying a predictor in sample  $c^t$  trained based on sample  $c^{t'}$  are defined as above except  $c^{t'}$  is interchanged with  $c^t$ .

The specific predictors we used were regression trees<sup>27</sup>. Formally we define a regression tree, *T*, to have a set of split nodes *S* and a set of a leaf nodes *N*. A split node  $s \in S$  can be represented by the 4-tuple (f, v, l, r) where *f* is a feature used to the split the data, *v* is the value of feature *f* on which the split is based, and *l* and *r* are nodes in  $S \cup N$ . A leaf node  $n \in N$  can be represented by a 1-tuple (e) which is the prediction value associated with the node. In addition one node  $w \in S \cup N$  is designated as the root of the tree. We let *u* denote a vector of feature values for which an output prediction should be generated. To generate a prediction we start by setting a variable *z* to the root node *w*, and then while *z* is not a leaf node, if *u*. (*z*.*f*) *z*.*v* we let z=z.l and otherwise z=z.r where *u*.*x* refers to feature *x* of vector *u*. Once *z* is a leaf node the prediction of *z*.*e* is made.

We learn regressions trees for a mark  $m_t$  based on sample  $c^t$  for a set of sampled positions P recursively. We define a node creation procedure that takes as input a set x of positions and identifies a feature, f, and split value, v, on which to split the positions. In the procedure we

define the sets  $X_{L_{f,v}} = \left\{ p \in X | u_{c^{t'},m^t,p} \cdot f \leq v \right\}$  and  $X_{R_{f,v}} = \left\{ p \in X | u_{c^{t'},m^t,p} \cdot f > v \right\}$  where  $u_{c^{t'},m^t,p} \cdot f$  corresponds to the feature value f of the feature vector for position p as defined above when considering  $m^t$  based on sample  $c^{t'}$ . If the set

 $\{f, v | |X_{L_{f,v}}| \ge 20 \land |X_{R_{f,v}}| \ge 20\}$  is empty meaning there is no split that can be created with both subsets of the partition containing at least 20 data points, a constraint intended to reduce overfitting, then we create a leaf node *n* where the associated output prediction of the

node *n.e* is set to  $\frac{1}{|X|} \sum_{p \in X} o_{c^{t'}, m^{t}, p}$  that is the average value at all positions in *X*, otherwise we create a split node *s* and set *s.f* and *s.v* to *f* and *v* respectively based on:

$$argmin_{\left\{f,v \mid \mid X_{L_{f,v}} \mid \geq 20 \land \mid X_{R_{f,v}} \mid \geq 20\right\}} \left( \sum_{p \in X_{L_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{L_{f,v}} \mid} \sum_{p' \in X_{L_{f,v}}} o_{c^{t'}m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid X_{R_{f,v}} \mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \left( o_{c^{t'},m^{t},p} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \left( o_{c^{t'},m^{t},p'} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \left( o_{c^{t'},m^{t},p'} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \left( o_{c^{t'},m^{t},p'} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} - \frac{1}{\mid} \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} \right)^{2} + \sum_{p \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} - \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t'},p'} - \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t},p'} - \sum_{p' \in X_{R_{f,v}}} o_{c^{t'},m^{t'},p'} - \sum_{p' \in X_$$

This chooses a split that minimizes the squared error of the resulting output prediction subject to the constraint that both subsets of the partition have at least 20 data points. We then set *s.l* and *s.r* to the nodes created by applying the node creation procedures to set of positions  $X_{L_{f,v}}$  and  $X_{R_{f,v}}$  respectively. Ties for the best split feature and value were broken randomly. Input data was rounded to the nearest tenth, for generating features, training, and applying the predictors, and only those values present in the training data were considered as split values. DNA methylation values were treated as percentages for the purposes of this

rounding, but the final output for DNA methylation was reported as a fraction. The node creation procedure is initially called with all positions in P which creates the root node.

To make a prediction in sample  $c^t$  for mark  $m^t$  at position p we compute

 $\frac{1}{b|C_{m_{t}} \setminus \{c_{t}\}|} \sum\nolimits_{c_{t'} \in C_{m_{t}}} \setminus \{c_{t}\} \sum\nolimits_{i=1}^{b} T_{c_{t'}, m_{t}, P_{i}}\left(u_{c_{t}, m_{t}, p}\right)$ 

where *b* is number of sets of sampled positions and  $T_{c_{t'},m_t,P_i}(u_{c_t,m_t,p})$  denotes the prediction made by the regression tree trained on sample  $c^{t'}$  to predict mark  $m^t$  using the set of sampled positions  $P_i$  when applied to the feature vector defined as above for predicting mark  $m^t$  in sample  $c^t$  at position *p*.

Each set of positions for training contained 100,000 randomly sampled positions. We used one set of positions for training, except for predicting the Tier-3 marks in the primary imputation and all marks in the imputation restricted to the seven samples with deep coverage of many marks (E003, E004, E005, E006, E007, E008, E017)<sup>10</sup> where we trained predictors based on three independent 100,000 position samples since we had a limited number of different samples based on which to train predictors. If the set of features that could be defined for a target sample in training is empty, which happened when evaluating predictive performance when holding out some features, we excluded that predictor from the ensemble.

All predictions except for DNA methylation were at a 25bp resolution. For DNA methylation we made base predictions just at the positions of CpGs, but the features based on other marks were still computed at a 25bp resolution. We did not make explicit predictions for positions within the first and last 10kb of each chromosome, and instead 0 was used as the signal value there except for DNA methylation where it was 0.5.

For the primary imputation the tier assignments of marks determined which marks were eligible to be used to impute other marks (**Fig. S2**), and we made predictions across chr1-22 and chrX. For the purpose of evaluating imputation performance with subsets of features and marks unbiased by the deep coverage of certain marks, we did a separate set of imputations using only the seven samples with deep mark coverage. For this set of imputations we treated the Tier 1-3 marks the same and the method could use any of the available marks within these tiers to predict any other mark. For these evaluations we made predictions only on chr10.

In order to handle the computational demands of training an ensemble of predictors and then applying them to generate genomewide predictions for more than 4,000 datasets we first wrote out to disk for the randomly sampled positions feature instances for each mark and sample. The set of feature instances for a mark and sample written out were sufficient to be used to train predictors based on the sample for the goal of predicting the mark in any other sample. Depending on the overall target sample, different subsets of the features would be used consistent with what is described above, but this step allowed significant reuse of computation and memory when imputing the same mark across multiple samples. Once the

training instances were written out different predictors could be trained in parallel. Applying the predictors to impute genomewide values was parallelized over different samples, marks, and chromosomes. To more efficiently compute the ordering of the locally nearest samples at each position when making genomewide predictions, a computationally demanding step, we leveraged information on the ordering of the nearest samples at the previously considered position, which would often be highly similar.

# Comparison with Linear Regression, Nearest Neighbor, and Single Sample Training Predictions

For the linear regression and nearest neighbor comparison we limited the predictions to chr10. The linear regression was the weka (v.3.7.3)<sup>51</sup> implementation with a ridge regularization parameter set to 1. For the comparison with nearest neighbor approaches we used up to the ten nearest neighbors defined by H3K4me1 and for both the local and global distance as defined above. We selected H3K4me1 as it was defined in all samples and associated with more sample specific patterns<sup>3,4</sup>. For predicting H3K4me1 we used H3K4me3 instead. Similarly for the comparison with training based on a single nearest sample we selected the nearest sample based on global H3K4me1 correlation, except using H3K4me3 when predicting H3K4me1.

# Gene Annotations, Expression, Conserved Elements

For gene annotation enrichments we used a modified version of the GENCODE 10 gene annotations<sup>52</sup> that only included long transcripts as used in (Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup>. For defining a set of expressed genes in each sample we combined the protein coding genes and non-coding RNAs sets selecting those transcripts that had an RPKM >=0.5 as processed in (Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup>. The evolutionary conserved elements were the hg19 liftover of the PI conserved elements previously reported<sup>38,53</sup>.

# **Signal Heatmap Clustering**

The signal heatmaps were generated by first randomly selecting 2,000 25-bp intervals in the genome, which form one dimension of each matrix. The other dimension corresponds to different samples in which the mark was observed. The ordering of elements in both dimensions of the matrix were determined using the Matlab implementation of hierarchical clustering and optimal leaf ordering<sup>54</sup> applied to the observed data. Correlation distance was used except to cluster the rows for DNA methylation, H3K23me3, H4K5ac, RNA-seq where Euclidean distance was used because of zero variance rows. The imputed data matrix is based on using the same ordering of rows and columns as generated based on the observed data.

## **Chromatin States Based on Imputed Data**

Chromatin states were learned on the imputed data using ChromHMM<sup>21</sup>. The data was binarized at a 200-bp resolution by averaging the eight 25-bp intervals overlapping and using an average signal threshold of 2. Two types of models were learned. One model used the 12-Tier-1 and 2 marks across all 127 samples. The second model was based on all

Tier-1-3 marks imputed in all the seven samples with deep mark coverage, where we had a more confident imputation of the Tier-3 marks. Both posterior probabilities soft-assignments for each state and hard assignments based on the maximum posterior were produced, but all the chromatin state analyses were based on the hard assignments. Chromatin states based on the observed data were obtained from (Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup>.

The chromatin state assignment recovery based on the maps of a subset of marks was determined using the *EvalSubset* command of ChromHMM<sup>21</sup>. This is similar to a procedure previously described<sup>20</sup>, but based on hard assignments.

# Single Mark Peak Calls

Macs2 (version. 2.0.10)<sup>55</sup> was used to call peaks on the imputed signal data. The bdgpeakcall command was used to generate narrowPeaks while the bdgbroadcall command to generate gappedPeaks with the '-c' cutoff flag set to 2. These peak calls were compared to corresponding peak calls based on the observed data obtained from (Roadmap Epigenomics Consortium et al, 2015)<sup>10</sup> that were also generated based on Macs2 but based on the callpeak applied to aligned reads.

# **Comparison with Genome-wide Association Study Analysis**

We obtained the contents of the NHGRI GWAS Catalog<sup>33</sup> on September 12, 2014 through the UCSC Genome Browser<sup>56</sup>. We grouped entries into studies based on a unique combination of pubmed ID and trait combination. We filtered the set of SNPs in each study such that no two SNPs were within 1MB of each other on the same chromosome. We did this by ranking the SNPs in a study based on their p-value significance, and then filtering a SNP if it was within 1MB of any higher ranked SNP that was not filtered. We tested the significance of the signal level for observed and separately imputed data associated with a set of SNPs in a study compared to all other GWAS catalog SNPs after the filtering using a Mann-Whitney U Test as implemented in the Apache Commons Math 3.3 library. For each mark and separately for the observed and imputed data, we computed estimated False Discovery Rates (FDRs) at each p-value threshold controlling for testing multiple study and sample combinations. We did this by generating 100 random permutations of the study assignments among the set of filtered SNPs across all studies, and then re-computed the significance of the signal associations. The FDRs corresponding to a p-value were estimated by computing the average number of sample-study combinations that reached that significance threshold for a permuted catalog divided by the total number of combinations that reached the significance threshold based on the actual catalog. If a less significant pvalue had an initial lower FDR estimate than a more significant p-value, then the more significant p-value also received that lower FDR estimate. We displayed the first ten permutations generated in the p-value comparison plots. For the comparison of the most significant imputed sample with the average signal, the FDR for the average signal only needed to control for testing multiple studies as there was not sample specific predictions. In this specific comparison the FDR for the imputed data was determined as above, but by only considering the most significant p-value across all samples for a specific study for both the actual and each randomized catalog.

# **Motif Analysis**

The motif analysis was conducted for each sample in which there was DNase data available. The foreground for the enrichment was those locations which had DNase signal above 5 in the observed data and below 1 in the imputed data. The background for the enrichment was restricted to all locations which had observed DNase signal above 5. An additional analysis was done where the foreground was all locations that had observed DNase signal above 5, with a genomewide background. The motif analysis was conducted using a previously described software and assembled compendium of motifs<sup>57</sup>.

# Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

# Acknowledgements

We thank Anshul Kundaje, Wouter Meuleman, Misha Bilensky, and members of the NIH Roadmap Epigenomics EDACC for data processing. We thank Pouya Kheradpour for advice on the motif analysis. We thank Matt Eaton for generating the chromatin state segmentation visualization. We thank Nisha Rajagopal, Bing Ren, and members of the Kellis lab and Roadmap Epigenomics consortium for discussions related to this work. We thank the NIH Roadmap Epigenomics and ENCODE consortia for generating the data used in this paper. Funding for this work provided by NSF CAREER Award # 1254200 and an Alfred P. Sloan Fellowship to JE and by NIH through NHGRI grants RC1HG005334 and R01HG004037 to MK.


# References

- 1. Barski A, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129:823–837. [PubMed: 17512414]
- ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74. [PubMed: 22955616]
- 3. Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011; 473:43–49. [PubMed: 21441907]
- Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009; 459:108–112. [PubMed: 19295514]
- Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009; 462:315–322. [PubMed: 19829295]
- Thurman RE, et al. The accessible chromatin landscape of the human genome. Nature. 2012; 489:75–82. [PubMed: 22955617]
- 7. Zhu J, et al. Genome-wide Chromatin State Transitions Associated with Developmental and Environmental Cues. Cell. 2013; 152:642–654. [PubMed: 23333102]
- 8. Ziller MJ, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013; 500:477–481. [PubMed: 23925113]
- Xie W, et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell. 2013; 153:1134–1148. [PubMed: 23664764]
- Roadmap Epigenomics Consortium. et al. Integrative Analysis of 111 Human Reference Epigenomes. Nature. 2015
- Troyanskaya O, et al. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001; 17:520–525. [PubMed: 11395428]
- Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 2010; 11:499–511. [PubMed: 20517342]
- Bock C, et al. CpG Island Methylation in Human Lymphocytes Is Highly Correlated with DNA Sequence, Repeats, and Predicted DNA Structure. PLoS Genet. 2006; 2:e26. [PubMed: 16520826]

- Das R, et al. Computational prediction of methylation status in human genomic sequences. Proc. Natl. Acad. Sci. 2006; 103:10713–10716. [PubMed: 16818882]
- Yuan G-C. Targeted recruitment of histone modifications in humans predicted by genomic sequences. J. Comput. Biol. J. Comput. Mol. Cell Biol. 2009; 16:341–355.
- Fan S, Zhang MQ, Zhang X. Histone methylation marks play important roles in predicting the methylation status of CpG islands. Biochem. Biophys. Res. Commun. 2008; 374:559–564. [PubMed: 18656446]
- Zheng H, Wu H, Li J, Jiang S-W. CpGIMethPred: computational model for predicting methylation status of CpG islands in human genome. BMC Med. Genomics. 2013; 6:S13. [PubMed: 23369266]
- Stevens M, et al. Estimating absolute methylation levels at single CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res. 2013 gr.152231.112 doi: 10.1101/gr.152231.112.
- Capra JA, Kostka D. Modeling DNA methylation dynamics with approaches from phylogenetics. Bioinformatics. 2014; 30:i408–i414. [PubMed: 25161227]
- Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 2010; 28:817–825. [PubMed: 20657582]
- Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods. 2012; 9:215–216. [PubMed: 22373907]
- 22. Hoffman MM, et al. Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat. Methods. 2012; 9:473–476. [PubMed: 22426492]
- 23. Karli R, Chung H-R, Lasserre J, Vlahovicek K, Vingron M. Histone modification levels are predictive for gene expression. Proc. Natl. Acad. Sci. U. S. A. 2010; 107:2926–2931.
- Lasserre J, Chung H-R, Vingron M. Finding Associations among Histone Modifications Using Sparse Partial Correlation Networks. PLoS Comput Biol. 2013; 9:e1003168. [PubMed: 24039558]
- 25. Yu H, Zhu S, Zhou B, Xue H, Han J-DJ. Inferring causal relationships among different histone modifications and gene expression. Genome Res. 2008; 18:1314–1324. [PubMed: 18562678]
- Zhou J, Troyanskaya OG. Global quantitative modeling of chromatin factor interactions. PLoS Comput. Biol. 2014; 10:e1003525. [PubMed: 24675896]
- 27. Hastie, T.; Tibshirani, R.; Friedman, J. The Elements of Statistical Learning. Springer; 2009.
- Zhou X, et al. The Human Epigenome Browser at Washington University. Nat. Methods. 2011; 8:989–990. [PubMed: 22127213]
- 29. Raney BJ, et al. Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser. Bioinformatics. 2014; 30:1003–1005. [PubMed: 24227676]
- Harris RA, et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat. Biotechnol. 2010; 28:1097–1105. [PubMed: 20852635]
- Bolstad BM, Irizarry RA, Åstrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19:185–193. [PubMed: 12538238]
- Maurano MT, et al. Systematic Localization of Common Disease-Associated Variation in Regulatory DNA. Science. 2012; 337:1190–1195. [PubMed: 22955828]
- Hindorff LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 2009; 106:9362–9367. [PubMed: 19474294]
- John S, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011; 43:264–268. [PubMed: 21258342]
- 35. Fejes AP, et al. FindPeaks 3.1: a tool for identifying areas of enrichment from massively parallel short-read sequencing technology. Bioinforma. Oxf. Engl. 2008; 24:1729–1730.
- Landt SG, et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 2012; 22:1813–1831. [PubMed: 22955991]
- 37. Sanyanusin P, et al. Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat. Genet. 1995; 9:358–364. [PubMed: 7795640]

- Lindblad-Toh K, et al. A high-resolution map of human evolutionary constraint using 29 mammals. Nature. 2011; 478:476–482. [PubMed: 21993624]
- 39. Song L, et al. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res. 2011; 21:1757–1767. [PubMed: 21750106]
- 40. Bernstein BE, et al. A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells. Cell. 2006; 125:315–326. [PubMed: 16630819]
- 41. Eskandarian HA, et al. A Role for SIRT2-Dependent Histone H3K18 Deacetylation in Bacterial Infection. Science. 2013; 341:1238858. [PubMed: 23908241]
- Barber MF, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012; 487:114–118. [PubMed: 22722849]
- 43. Ferrari R, et al. Epigenetic Reprogramming by Adenovirus e1a. Science. 2008; 321:1086–1088. [PubMed: 18719284]
- Horwitz GA, et al. Adenovirus Small e1a Alters Global Patterns of Histone Modification. Science. 2008; 321:1084–1085. [PubMed: 18719283]
- 45. Seligson DB, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005; 435:1262–1266. [PubMed: 15988529]
- 46. Kouskouti A, Talianidis I. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J. 2005; 24:347–357. [PubMed: 15616580]
- Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011; 25:1345–1358. [PubMed: 21724828]
- Kasowski M, et al. Extensive variation in chromatin states across humans. Science. 2013; 342:750–752. [PubMed: 24136358]
- 49. McVicker G, et al. Identification of Genetic Variants That Affect Histone Modifications in Human Cells. Science. 2013; 342:747–749. [PubMed: 24136359]
- 50. Kilpinen H, et al. Coordinated Effects of Sequence Variation on DNA Binding, Chromatin Structure, and Transcription. Science. 2013; 342:744–747. [PubMed: 24136355]
- 51. Hall M, et al. The WEKA Data Mining Software: An Update. SIGKDD Explor Newsl. 2009; 11:10–18.
- Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22:1775–1789. [PubMed: 22955988]
- 53. Garber M, et al. Identifying novel constrained elements by exploiting biased substitution patterns. Bioinformatics. 2009; 25:i54–i62. [PubMed: 19478016]
- 54. Bar-Joseph Z, Gifford DK, Jaakkola TS. Fast optimal leaf ordering for hierarchical clustering. Bioinformatics. 2001; 17:S22. [PubMed: 11472989]
- 55. Zhang Y, et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 2008; 9:R137. [PubMed: 18798982]
- Karolchik D, et al. The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res. 2008; 36:D773–9. [PubMed: 18086701]
- 57. Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res. 2014; 42:2976–2987. [PubMed: 24335146]

Ernst and Kellis




## Figure 1. Application and Method Overview

(a) Matrix of observed and imputed datasets across 127 reference epigenomes ('samples'), including 111 from the Roadmap Epigenomics project (rows 1-111) grouped and colored by cell/tissue type, and an additional 16 by ENCODE (rows 112-127), with reference epigenome identifier (EID) and short sample/tissue description. Epigenomic marks (top) are grouped by Tier1-Tier3 plus RNA-seq and DNA-methylation, based on experimental coverage and imputation strategy. Black dotted arrows on the top right denote E017 datasets shown in panel b (horizontal arrow), and H3K36me3 datasets shown in panel c (vertical arrow), illustrating the two dimensions of correlations used in ChromImpute and shown in panel d. (b) Correlation between epigenomic marks in the same sample, one of the two classes of features used for epigenome imputation. Datasets from sample E017 are shown illustrating their highly correlated nature, comparing the observed signal for H3K4me1 from E017 (gray), the imputed data (red) which was imputed without using the observed data, and

the observed tracks for other marks (blue), ordered based on their correlation with the H3K4me1. Imputation of H3K4me1 in E017 (red) does not use the observed data (gray), and instead uses the other samples to learn relationships between H3K4me1 and other marks. For the primary imputation of H3K4me1, not all marks shown were used, as only Tier-1 marks are used to impute Tier-1 marks. (c) Multiple signal tracks for H3K36me3 across samples illustrate the highly correlated nature of a given mark across samples, exploited in the second class of features used for epigenome imputation. This example uses the same region as panel **a** to compare the observed signal for H3K36me3 in E017 (gray), H3K36me3 in several other samples (blue), which constitute the basis for highlyinformative features for H3K36me3 imputation in E017 (red). Observed tracks (blue) are ordered by their global correlation to the observed H3K36me3 signal in E017, though ChromImpute does not have this information when imputing H3K36me3 in E017, and instead determines sample similarity based on other marks, both globally and locally at each position, and then uses the H3K36me3 signal in up to ten most-proximal samples for each definition of similarity to compute individual features for each predictor of the ensemble (panel d, center). (d) Ensemble strategy for signal track imputation using features that exploit correlations between marks in the same sample (left) and correlations between samples for a given mark (right). We assume that no information is available for the target mark in the target sample (gray targets). Thus, we learn relationships between marks (left side) in other samples (column of E1 sample is not used), and learn relationships between samples (right side) using other marks from which we compute same-mark features. The ensemble predictor that combines features across marks (b) and across samples (c) is learned only in other samples (top), and the marks in the target sample are only used during the actual application of the learned ensemble predictors to compute the imputed signals.


Ernst and Kellis



# Figure 2. Imputed data is a close match to observed datasets

(a) Visualization of one of the randomly-selected 200kb regions, illustrates high-resolution concordance between observed (blue) and imputed (red) signal tracks. Imputed tracks are generated at 1-bp resolution for DNA methylation and 25-bp resolution for all other marks, and trained without using the observed track. For each mark (row), we show a randomly selected sample (EID from **Fig. 1a**), which also contains observed data for comparison (light purple entries in **Fig. 1a**). This region was selected among nine randomly-selected 200kb regions (**Fig. S3**) as the one with the most signal across all marks. Larger 1.5Mb context,

and example 5kb close-up are shown in **Fig. S3c**, illustrating concordance at multiple resolutions. (b) Visualization of 2,000 randomly-selected 25-bp regions (columns), and their signal (yellow=high, blue=low) across up to 127 samples (rows, colored as in Fig. 1a), for Tier-1 marks(yellow sidebar) and RNA-seq and DNA-methylation (green sidebar) (Tier-2 and Tier-3 marks are shown in Fig. S4). Rows and columns are clustered for each mark independently to highlight structure based on observed data (top), and imputed data (generated without using the corresponding observed dataset) is shown below, in the same order, showing clear similarity. (c) Quantitative comparison of observed signal correlation for ChromImpute (red), averaging the mark signal from all other samples (green), and the best-case for selecting a single sample (blue), which is not a realistic method when the target mark signal is not known, as it would be needed to determine the single-best sample. Average correlation is computed based on all samples for which both observed and imputed signals are available. ChromImpute shows consistently higher correlation of observed signals than the two alternate methods (including the unrealistic best-case) for all marks and for both metrics. For additional comparisons see Fig. S5-7. (d) AUC for recovering bases covered by a narrow peak call on observed data<sup>10</sup> when ranking based on predicted signal.




# Figure 3. Imputed data shows higher TSS/gene recovery, robustness, and biological group recovery

(a,b) Quantitative comparison of observed (blue) and imputed (red) data in their recovery of annotated promoters (a) and gene bodies (b), based on the area under the ROC curve up to a 5% false positive rate (y-axis) for H3K4me3 signal recovery of locations within 2kb of transcription start sites (a) and H3K36me3 signal recovery of gene bodies (b). Arrows indicate two fetal brain samples (E081 and E082) with very different values in the observed data, which show much higher (and more consistent) recovery for imputed data. (c,d) Comparison of aggregate signal for imputed (red) and observed (blue) datasets based on -

log<sub>10</sub> p-value of H3K4me3 surrounding the TSS (c) and H3K36me3 in gene bodies (d). Imputed data show significantly more consistent profile across all datasets, and in particular for the two fetal brain samples (E081, E082), which show substantial differences in the observed data. (e) Pairwise comparison of genome-wide signal correlation for all samples using observed (blue) and imputed (red) data for H3K4me1, H3K27me3, and DNase (additional marks shown in Fig. S19), with samples ordered and colored as in Fig. 1a (left sidebar). Imputed datasets better capture biological relationships between samples than observed datasets, with their correlation structure clearly delineating pluripotent cells, immune cells, adult brain, and multiple tissue groups (Fig. 1a), while observed datasets are much less correlated even for highly similar samples. (f) Area under the ROC curve for classifying whether two different pairs of experiments belong to the same group when ranking the pairs based on their correlation. A value of 0.5 could be achieved by a random guessing and a value of 1.0 is the maximum possible score. The 'Other' and 'ENCODE' groups were excluded from this analysis as well as imputed pairs that were not present in the observed data. This shows quantitatively that the relative similarity of imputed data sets is more consistent with the biological groupings of the samples.

Ernst and Kellis

Page 31




### Figure 4. Overlap with trait-associated genetic variants from GWAS

(a) (Left) The x-axis shows the number of genome-wide association studies for which there was at least one sample for which the H3K27ac signal was significantly different than based on a background of all GWAS catalog SNPs at significance level indicated on the y-axis using a Mann-whitney U Test (**see Methods**). This is shown for the observed data (blue), the imputed data restricted to the 98 samples with observed data (red), and the observed and imputed data based on ten randomizations of the GWAS catalog. (Right) The same as on left, but counting study-sample combinations opposed to just studies. (**b**) A scatter plot

showing the  $-\log_{10}$  p-value computed for each study-sample combination based on the observed data (x-axis) and imputed data (y-axis) for each combination that had a p-value of  $10^{-3}$  or better based on either the imputed or the observed data for H3K27ac. The diagonal line is the y=x line showing most of the highest significant studies based on either the observed or imputed data are above it. Additional marks can be found in **Fig. S24-26**. (**c-f**) Enrichment matrices (heatmaps) showing all studies (rows) with uncorrected  $-\log_{10}$  p-value

3.5 for at least one reference epigenome (columns) based on H3K27ac imputed data **c,e** and observed data **d,f**. For each study (rows) is shown the trait, most-significant p-value ( $\log_{10}$  p), max-sample abbreviation (Abbr), and pubmed identifier (PMID). Only samples that showed the highest-significance positive enrichment for at least one study are shown. **c,d:** studies that were significant (-logP 3.5) for both observed and imputed. Top three rows show studies with broad enrichment across samples. **e,f**: Same enrichments for studies that were only significantly enriched using imputed (e) or observed (f) H3K27ac signal. Stars denote H3K27ac signal tracks that only exist as imputed data. Expanded enrichments for all samples, all Tier-1 marks, and additional GWA studies are in **Table S2**.


a.



**Figure 5.** Low similarity between imputed and observed data reveals low-quality datasets (a) Comparison of quality control (QC) metrics (columns) for the ten datasets (rows) showing lowest agreement with gene and TSS annotations (**Fig. 3a,b**), based on H3K4me3 PromRecov (top) and H3K36me3 GeneRecov (bottom). Each entry shows rank (out of 127) for PromRecov/GeneRecov, read depth, and each QC metric (Poisson statistic, Signal Proportion of Tags, FindPeaks, Normalized and Relative Strand Correlation between forward and reverse strands (NSC and RSC)), and similarity between imputed and observed data (Match1 and GWcorr). Orange-shaded EIDs denote the five worst-agreement datasets

from panel **b**. Data sets with the same read depth, (due to highly sequenced data sets being previously downsampled to the same number of reads<sup>10</sup>), are given the same expected rank if ties were broken randomly. Most-problematic datasets (based on lack of gene or +/-2kbTSS annotation recovery) are sometimes missed by traditional QC measures, but consistently show low imputation agreement. (b) Distribution of agreement between top 1% observed signal and top 1% imputed signal locations for H3K4me3 (top) and H3K36me3 (bottom), highlighting five worst-similarity (orange) and five highest-similarity (green) datasets. (c) Observed (blue) and imputed (red) signal tracks for worst-similarity (orange) and best-similarity (green) datasets for H3K4me3 (top) and H3K36me3 (bottom) for the entire chromosome 10 (0-135Mb). Datasets with the lowest agreement have relatively flat signal, suggesting that when observed and imputed datasets disagree most, it is usually the observed datasets that are of lowest quality. (d) Aggregation of observed signal for H3K4me3 in TSS (top) and H3K36me3 in gene bodies (bottom) for the 5 best-agreement (green) and worst-agreement (orange) datasets, highlighting the unusual profiles of some worst-agreement datasets, suggesting they are of lower quality, even though they were not flagged by traditional QC metrics.

Ernst and Kellis



#### Figure 6. Imputation using mark subsets and chromatin state learning

(a) Imputation agreement for each mark (columns) using subsets of features (rows) in top 1% signal bins, or 0.25 concordance measure for DNA methylation, for Chr10 relative to agreement achieved when using all features based on the seven samples with deep mark coverage without making distinctions between the Tier 1-3 marks. Same-sample features are most important for acetylation marks, and same-mark features most important for H3K27me3, H3K36me3, H3K9me3, and RNA-Seq. Profiling of only H3K18ac and H3K79me2 imputation allows higher relative imputation agreement than all five core marks assuming a compendium with uniform coverage of marks. Performance for additional subsets is shown in **Fig. S42**. The last two columns show the average performance of the feature subset over all target marks and specifically for acetylations. For the purpose of computing these averages for mark subsets, if the target mark was included in the subset

then a value of 1 was used for the target mark, though the imputation performance restricted to other marks in the subset when available is provided in the table. The H3K18ac +H3K79me2 and Tier-1 and 2 mark evaluations were limited to the five samples that were deeply-profiled across marks and also had experimentally-profiled H3K79me2. (b) Portion of a chromatin state segmentation using imputed data of 12 marks across 127 samples using the 25-state model and colors shown in panel c. Segmentation is highly consistent for similar samples, but able to capture highly dynamic regulatory elements across different samples. (c) Chromatin state model using 12 marks and 25 states, learned jointly using imputed data across all 127 samples. For each state (rows) are shown its emission parameters, genome coverage, relative functional enrichments for diverse annotations and conserved elements, and median observed and imputed DNA methylation and RNA-Seq signal (also see Fig. S33), followed by a candidate state annotation. (d) Expanded chromatin state model learned using 50 states and 29 marks in seven samples with deep mark coverage. States are grouped and labeled by the maximum-enrichment 25-state model match. Emission parameters and functional enrichments (similar to c), and percentage of locations recovered for each state using subsets of marks (also see Fig. S40,S41,S43). +H3K18ac denotes the subset of Tier-1 and 2 marks extended by H3K18ac. When the same chromatin state was not maximallyrecovered with Tier-1 and 2 marks, the last two columns denote the best other state and its percent assignment.